The Malaysia IVIG market was valued at $12,277 thousand in 2015, and is projected to reach $18,649 thousand by 2022, registering a CAGR of 6.1% during the forecast period. This is attributed to increase in prevalence of chronic inflammatory demyelinating polyneuropathy (CIDP) & hypogammaglobulinemia and rise in use of immunoglobulins to treat Guillain-Barre syndrome (GBS), inflammatory myopathies, specific antibody deficiency, and others. Increase in geriatric population & number of hemophilic patients, improved IVIG production owing to the emergence of advanced technologies, and enhanced purification techniques (with better plasma yield) drive the growth of the market. However, stringent government regulations toward IVIG products, expensive therapy, and high risk of side effects associated with the use of IVIG are expected to hamper the market growth.
The report segments the Malaysia IVIG market based on application, product type, mode of delivery, and concentration by both- value and volume. Applications covered in the study include hypogammaglobulinemia, CIDP, immunodeficiency diseases, myasthenia gravis, multifocal motor neuropathy, idiopathic thrombocytopenic purpura (ITP), inflammatory myopathies, specific antibody deficiency, GBS, Kawasaki disease, secondary immune deficiency disease, and others.
Hypogammaglobulinemia and CIDP held dominant market shares in 2015 due to the large patient population and unavailability of effective alternatives to IVIG treatment. Based on product type, the market is segmented into immunoglobulin G (IgG), IgA, IgM, IgE, and IgD. By mode of delivery, it is bifurcated into intravenous, subcutaneous, and intramuscular. On the basis of concentration, it is categorized into 5%, 10%, and others. The intravenous mode of delivery segment held the largest revenue share in 2015, and is anticipated to continue this trend during the forecast period.
KEY PLAYERS PROFILED
Green Cross Corporation
Bio Products Laboratory Ltd.
Omrix Biopharmaceuticals Ltd.
Baxter International Inc.
KEY MARKET BENEFITS FOR STAKEHOLDERS
The study provides an in-depth analysis of the Malaysia IVIG market and the current trends and future estimations to elucidate the imminent investment pockets.
The report presents quantitative analysis of the market from 2014 to 2022 to enable stakeholders to capitalize on the prevailing market opportunities.
Extensive analysis of the market based on applications assists to understand the trends in the industry.
Key market players and their strategies are thoroughly analyzed to understand the competitive outlook of the market.
KEY MARKET SEGMENTS
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Multifocal Motor Neuropathy
Idiopathic Thrombocytopenic Purpura (ITP)
Specific Antibody Deficiency
Secondary Immune Deficiency
By Mode of Delivery
The other players in the value chain include (profiles not included in the report)
BDI Pharma, Inc.
China Biologics Products, Inc.
Hualan Biological Engineering Inc.
Guizhou Taibang Biological Products Co., Ltd.
Beijing Tiantan Biological Products Co., Ltd.
Shanghai Raas Blood Products Co. Ltd.
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS FOR STAKEHOLDERS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2 EXECUTIVE SUMMARY
2.1. CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. OVERVIEW OF IVIG
3.2.1. Patented products
3.3. EPIDEMIOLOGY AND ECONOMIC BURDEN OF CHRONIC CONDITIONS
3.4. COST OF SIDE EFFECTS DUE TO IVIG TREATMENTS
3.5. KEY FINDINGS
3.5.1. Top factors impacting Malaysia IVIG market
3.5.2. Top investment pockets
3.6. PORTERS FIVE FORCES ANALYSIS
3.7. VALUE CHAIN ANALYSIS
3.7.1. Primary activities
3.7.2. Support activities
3.8. PRODUCT SCENARIO IN IVIG MARKET
3.9. GOVERNMENT REGULATIONS AND REIMBURSEMENTS
3.10. COMPONENT ANALYSIS OF IMMUNOGLOBULIN G (IGG)
3.11. MARKET DYNAMICS
18.104.22.168. Rise in number of immunodeficiency diseases
22.214.171.124. Increase in adoption of IVIG
126.96.36.199. Increase in number of people with bleeding disorders
188.8.131.52. Rise in aging population
184.108.40.206. Stringent regulations
220.127.116.11. High cost of IVIG therapy
18.104.22.168. Untapped potential of Malaysia as an emerging economy
22.214.171.124. Development of cost-effective therapeutics through large-scale production
CHAPTER 4 MALAYSIA IVIG MARKET, BY APPLICATION
4.1.1. Market size and forecast
4.2.1. Market size and forecast
4.3. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIPD)
4.3.1. Market size and forecast
4.4. IMMUNODEFICIENCY DISEASES (ID)
4.4.1. Market size and forecast
4.5. MYASTHENIA GRAVIS (MG)
4.5.1. Market size and forecast
4.6. MULTIFOCAL MOTOR NEUROPATHY (MMN)
4.6.1. Market size and forecast
4.7. PRIMARY IMMUNE THROMBOCYTOPENIC PURPURA (PITP)
4.7.1. Market size and forecast
4.8. INFLAMMATORY MYOPATHIES (IM)
4.8.1. Market size and forecast
4.9. SPECIFIC ANTIBODY DEFICIENCY (SAD)
4.9.1. Market size and forecast
4.10. GUILLAIN-BARR SYNDROME (GBS)
4.10.1. Market size and forecast
4.11. KAWASAKI DISEASE (KD)
4.11.1. Market size and forecast
4.12. SECONDARY IMMUNE DEFICIENCY (SID)
4.12.1. Market size and forecast
4.13.1. Market size and forecast
CHAPTER 5 MALAYSIA IVIG MARKET, BY PRODUCT
5.2.1. Key market trends
5.2.2. Clinical interpretations
5.3.1. Key market trends
5.3.2. Clinical interpretations
5.4.1. Key market trends
5.4.2. Clinical interpretations
5.5.1. Key market trends
5.5.2. Clinical interpretations
5.6.1. Key market trends
5.6.2. Clinical interpretations
CHAPTER 6 MALAYSIA IVIG MARKET, BY MODE OF DELIVERY
6.1.1. Market size and forecast
6.2. INTRAVENOUS MODE OF DELIVERY
6.2.1. Market size and forecast
6.3. SUBCUTANEOUS MODE OF DELIVERY
6.3.1. Market size and forecast
6.4. INTRAMUSCULAR MODE OF DELIVERY
6.4.1. Market size and forecast
CHAPTER 7 MALAYSIA IVIG MARKET, BY CONCENTRATION
7.1.1. Market size and forecast
7.2. 5% CONCENTRATION
7.2.1. Market size and forecast
7.3. 10% CONCENTRATION
7.3.1. Market size and forecast
7.4. OTHER CONCENTRATIONS
7.4.1. Market size and forecast
CHAPTER 8 COMPANY PROFILES
8.1. BAXTER INTERNATIONAL INC.
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.2. BAYER AG
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.3. BIOTEST AG
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance
8.3.6. Key strategic moves and developments
8.4. CSL LTD.
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.4.5. Business performance
8.4.6. Key strategic moves and developments
8.5. GREEN CROSS CORPORATION
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Business performance
8.5.6. Key strategic moves and developments
8.6. GRIFOLS S.A.
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance
8.6.6. Key strategic moves and developments
8.7. JOHNSON & JOHNSON
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance
8.8. KEDRION S.P.A.
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance
8.8.6. Key strategic moves and developments
8.9. OCTAPHARMA AG
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.9.5. Business performance
8.10. SHIRE PLC
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Product portfolio
8.10.4. Business performance
8.10.5. Key strategic moves and developments
The IVIG products gained significant attention in the recent years due to their high efficacy in the treatment of immune diseases. Prevalence of various antibody deficiency disorders such as common variable immune deficiency (CVID), specific antibody deficiency, and hypogammaglobulinemia, increase in IVIG indications, improved production & purification processes, growth in awareness towards antibody deficiency, and rare immune disorders among patient population drive the growth of the IVIG market.
However, high costs associated with the IVIG treatment; shortage of IVIG; and side effects of IVIG treatment such as headache, migraine, fever, usea or vomiting, and cough hinder the market growth. IVIG products are widely used for the treatment of immunodeficiency disease, ITP, chronic lymphocytic leukemia (CLL), Kawasaki disease, and others. The untapped potential of Malaysia as an emerging market and development of cost-effective therapeutics through large-scale production act as opportunities to the market players in this region.
Hypogammaglobulinemia and CIDP held domint market shares in 2015 due to the large patient population and uvailability of effective altertives to IVIG treatment. Based on product type, the market is segmented into immunoglobulin G (IgG), IgA, IgM, IgE, and IgD. On the basis of concentration, it is categorized into 5%, 10%, and others. By mode of delivery, it is bifurcated into intravenous, subcutaneous, and intramuscular mode of delivery. The intravenous mode of delivery segment held the largest revenue in 2015 and is anticipated to continue this trend during the forecast period. High bioavailability of immunoglobulins and rapid absorption rate offered by intravenous mode of delivery are the factors that supplement the growth of the intravenous mode of delivery IVIG market.
Key findings of the Malaysia IVIG Market:
Hypogammaglobulinemia accounted for the largest revenue in 2015 owing to the lack of effective substitute treatment, and early adoption of IVIG
Myasthenia gravis is anticipated grow at the fastest CARG of 9.1% in the forecast period.
The intravenous mode of delivery was the highest revenue generating segment in 2015 and is anticipated to continue this trend during the forecast period.
10% concentration held the highest market share in 2015. This trend is likely to continue throughout the forecast period.
The key companies profiled in the report include Grifols S.A., Octapharma AG, Green Cross Corporation, Baxalta (Shire), Bio Products Laboratory Ltd., Biotest AG, CSL Behring, Omrix Biopharmaceuticals Ltd., Bayer Healthcare, and Baxter Intertiol Inc.
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.